Tissue Expander DisorderNCT03586960
Use of a Novel Device for Stretch Relaxation During Mohs Surgery
A study testing Peak Force Measurement in people with Tissue Expander Disorder and Stress Strain Curve, run by Silver Falls Dermatology at 1 site in United States.
Trial summary
Closure of cutaneous defects is associated with many common and serious problems. For example, Mohs surgery involves the removal of skin and other soft tissues that have been proven to be infiltrated with cancer. Iterative stages of Mohs are processed and examined microscopically for residual tumor. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Tissue Expander Disorder, Stress Strain Curve, Tissue Expansion
- What is being tested?
- Peak Force Measurement
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jul 2018to 30 Sep 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Any wound that cannot be reapproximated upon tumor removal (These locations are often on the lower leg and scalp.)
- Age over 18 years
- Intact skin surrounding wound for at least 2.5 cm
Who cannot join
- Active infection
- Systemically unstable or unwell patient
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Silver Falls Dermtology
Salem, Oregon, 97302
Angie Tingle, 503-362-8385, atingle@silverfallsderm.net
William Lear, MD
About this study
Closure of cutaneous defects is associated with many common and serious problems. For example, Mohs surgery involves the removal of skin and other soft tissues that have been proven to be infiltrated with cancer. Iterative stages of Mohs are processed and examined microscopically for residual tumor. Using specialized mapping, the surgeon can effectively achieve a high cure rate and minimize removal of unaffected tissue. This process usually takes a total of 2-3 hours, since the patient waits while the tissue is being processed, and complete clearance of margins can take multiple stages. In many cases, a cutaneous defect is produced of significant size. In certain areas of high tension, such as scalp and lower leg, this mandates either a lengthy course of wound care or that the surgeon perform a graft or flap. In many cases, performance of a graft is undesirable due to lack of vascularity to support graft survival. Creation of flaps involves incision and undermining of large areas of tissue in order to achieve wound closure. There is a current need for alternatives to graft and flaps in these locations.
Human skin has biomechanical properties that can be harnessed to facilitate closure of larger wounds. Stress-relaxation refers to the natural relaxation exhibited by skin put under a given amount of tension (stress) over time. After a period of stress, the force required to close the wound is reduced. In a porcine skin wound model, there is a 40-60% reduction in stress after twenty minutes of stretch relaxation.
Read more
There are several classic methods of delivering this stretch to skin intraoperatively. Most simply, a towel clamp can be used to bring edges together. However, the clamp, which is a sharp stainless steel instrument, can damage tissues. There are also commercial devices such as TopClosure. However, this device is intended for very large wounds with side plates that must be sutured or stapled to patient skin.
The SUTUREGARD device presents a simple method to provide stress to a wound but not damage tissue. The SUTUREGARD device results in significantly lower pressure on the skin when compared with traditional sutures and creates a much greater volume of wound eversion than is possible with a traditional suturing method. Engineering tests performed at OSU showed that a given simple interrupted suture will exert about 30% less pressure on the skin when used performed with the device compared to without the device. With this protection, this creates the corollary that a suture could be safely tied to a greater force with the device than without. In animal testing, the device has been used on porcine wounds for up to 6 weeks, where it showed superior histologic tolerability over traditional sutures.
The investigators have used the device to provide stress-relaxation within our clinic over the past several months and have seen reductions in wound width of about 30% with retention of the device for 30-60 minutes. Wounds exhibit significantly more reduction in width with overnight use. Unlike traditional retention sutures, which damage the skin, the skin appears normal with retention of the device for up to 2 days in our patients. Furthermore, all wounds that have been stress-relaxed with the device have healed without complication.
The investigators plan to study the stress-relaxation created by use of a SUTUREGARD device applied to cutaneous defects for a specified time periods (30, 60 and 90 minutes).
- Being tested
- Peak Force Measurement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peak Force MeasurementDevice
Force will be measured at 5,10, and 30 minutes
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group | Experimental | Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge. Receives: Device: Peak Force Measurement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Direct measurements of wound dimensions at each timepoint
Measurements will be taken at each time point of wound size
Measured: 5 minutes
Direct measurements of wound dimensions at each timepoint
Measurements will be taken at each time point of wound size
Measured: 10 minutes
Direct measurements of wound dimensions at each timepoint
Measurements will be taken at each time point of wound size
Measured: 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2018
- Study start2 Jul 2018
- Primary completion31 Aug 2018 (estimated)
- Study completion30 Sep 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Tissue Expander DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Silver Falls Dermatology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03586960
- Sponsor's protocol ID
- IRB18-025
- Status last verified
- Jul 2018
- First submitted
- 2 Jul 2018
- Last updated
- 16 Jul 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Saqib NU, Domenick N, Cho JS, Marone L, Leers S, Makaroun MS, Chaer RA. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. J Vasc Surg. 2013 Mar;57(3):692-9. doi: 10.1016/j.jvs.2012.08.115. Epub 2013 Jan 23.
PubMed 23351646Townsend KL, Akeroyd J, Russell DS, Kruzic JJ, Robertson BL, Lear W. Comparing the Tolerability of a Novel Wound Closure Device Using a Porcine Wound Model. Adv Wound Care (New Rochelle). 2018 Jun 1;7(6):177-184. doi: 10.1089/wound.2017.0777.
PubMed 29892494Topaz M, Carmel NN, Topaz G, Li M, Li YZ. Stress-relaxation and tension relief system for immediate primary closure of large and huge soft tissue defects: an old-new concept: new concept for direct closure of large defects. Medicine (Baltimore). 2014 Dec;93(28):e234. doi: 10.1097/MD.0000000000000234.
PubMed 25526444Hussain SH, Limthongkul B, Humphreys TR. The biomechanical properties of the skin. Dermatol Surg. 2013 Feb;39(2):193-203. doi: 10.1111/dsu.12095. Epub 2013 Jan 25.
PubMed 23350638
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of a Novel Device for Stretch Relaxation During Mohs Surgery
- ClinicalTrials.gov ID
- NCT03586960
- Acronym / sponsor ID
- IRB18-025
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Silver Falls DermatologyUniversity, hospital or other
- Study start
- 2 Jul 2018 (actual)
- Primary completion
- 31 Aug 2018 (estimated)
- Study completion
- 30 Sep 2018 (estimated)
- First posted
- 16 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Closure of cutaneous defects is associated with many common and serious problems. For example, Mohs surgery involves the removal of skin and other soft tissues that have been proven to be infiltrated with cancer. Iterative stages of Mohs are processed and examined microscopically for residual tumor. Using specialized mapping, the surgeon can effectively achieve a high cure rate and minimize removal of unaffected tissue. This process usually takes a total of 2-3 hours, since the patient waits while the tissue is being processed, and complete clearance of margins can take multiple stages. In many cases, a cutaneous defect is produced of significant size. In certain areas of high tension, such as scalp and lower leg, this mandates either a lengthy course of wound care or that the surgeon perform a graft or flap. In many cases, performance of a graft is undesirable due to lack of vascularity to support graft survival. Creation of flaps involves incision and undermining of large areas of tissue in order to achieve wound closure. There is a current need for alternatives to graft and flaps in these locations.
Human skin has biomechanical properties that can be harnessed to facilitate closure of larger wounds. Stress-relaxation refers to the natural relaxation exhibited by skin put under a given amount of tension (stress) over time. After a period of stress, the force required to close the wound is reduced. In a porcine skin wound model, there is a 40-60% reduction in stress after twenty minutes of stretch relaxation.
There are several classic methods of delivering this stretch to skin intraoperatively. Most simply, a towel clamp can be used to bring edges together. However, the clamp, which is a sharp stainless steel instrument, can damage tissues. There are also commercial devices such as TopClosure. However, this device is intended for very large wounds with side plates that must be sutured or stapled to patient skin.
The SUTUREGARD device presents a simple method to provide stress to a wound but not damage tissue. The SUTUREGARD device results in significantly lower pressure on the skin when compared with traditional sutures and creates a much greater volume of wound eversion than is possible with a traditional suturing method. Engineering tests performed at OSU showed that a given simple interrupted suture will exert about 30% less pressure on the skin when used performed with the device compared to without the device. With this protection, this creates the corollary that a suture could be safely tied to a greater force with the device than without. In animal testing, the device has been used on porcine wounds for up to 6 weeks, where it showed superior histologic tolerability over traditional sutures.
The investigators have used the device to provide stress-relaxation within our clinic over the past several months and have seen reductions in wound width of about 30% with retention of the device for 30-60 minutes. Wounds exhibit significantly more reduction in width with overnight use. Unlike traditional retention sutures, which damage the skin, the skin appears normal with retention of the device for up to 2 days in our patients. Furthermore, all wounds that have been stress-relaxed with the device have healed without complication.
The investigators plan to study the stress-relaxation created by use of a SUTUREGARD device applied to cutaneous defects for a specified time periods (30, 60 and 90 minutes).
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental Group | Experimental | Device: Peak Force MeasurementPeak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Any wound that cannot be reapproximated upon tumor removal (These locations are often on the lower leg and scalp.)
- Age over 18 years
- Intact skin surrounding wound for at least 2.5 cm
Key exclusion criteria (2 listed)
- Active infection
- Systemically unstable or unwell patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peak Force MeasurementForce will be measured at 5,10, and 30 minutes | Device | Experimental Group |
Primary outcome
Direct measurements of wound dimensions at each timepoint
Time frame: 5 minutes
Measurements will be taken at each time point of wound size
Direct measurements of wound dimensions at each timepoint
Time frame: 10 minutes
Measurements will be taken at each time point of wound size
Direct measurements of wound dimensions at each timepoint
Time frame: 30 minutes
Measurements will be taken at each time point of wound size
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2018.
- Background: PubMed 23351646Saqib NU, Domenick N, Cho JS, Marone L, Leers S, Makaroun MS, Chaer RA. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. J Vasc Surg. 2013 Mar;57(3):692-9. doi: 10.1016/j.jvs.2012.08.115. Epub 2013 Jan 23.
- Background: PubMed 29892494Townsend KL, Akeroyd J, Russell DS, Kruzic JJ, Robertson BL, Lear W. Comparing the Tolerability of a Novel Wound Closure Device Using a Porcine Wound Model. Adv Wound Care (New Rochelle). 2018 Jun 1;7(6):177-184. doi: 10.1089/wound.2017.0777.
- Background: PubMed 25526444Topaz M, Carmel NN, Topaz G, Li M, Li YZ. Stress-relaxation and tension relief system for immediate primary closure of large and huge soft tissue defects: an old-new concept: new concept for direct closure of large defects. Medicine (Baltimore). 2014 Dec;93(28):e234. doi: 10.1097/MD.0000000000000234.
- Results publication: PubMed 23350638Hussain SH, Limthongkul B, Humphreys TR. The biomechanical properties of the skin. Dermatol Surg. 2013 Feb;39(2):193-203. doi: 10.1111/dsu.12095. Epub 2013 Jan 25.
- Individual participant dataSharing planned: No
Related trials for Tissue Expander Disorder
RecruitingPhase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
Breast Cancer
RecruitingObservational study
Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement
Breast Carcinoma
Not yet recruitingPhase 3
The Comparison Between DEDTI BR and T/E BR
Breast Cancer
Active, not recruitingObservational study
Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy
Breast Cancer, Breast Neoplasms
Not yet recruitingObservational study
EXpander-based Versus Direct to Implant PRE-pectoral Breast Reconstruction: a Comparative Analysis of Surgical Outcomes
Breast Cancer, Operable Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peak Force Measurement in people with Tissue Expander Disorder and Stress Strain Curve, run by Silver Falls Dermatology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Angie Tingle (503 362 8385, atingle@silverfallsderm.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Direct measurements of wound dimensions at each timepoint (time frame: 5 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03586960, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2018.